High-Risk Subgroups and MRD: An Updated Analysis of the Phase 3 ECHO Trial of Acalabrutinib with Bendamustine/Rituximab in Previously Untreated Mantle Cell Lymphoma

This article has no abstract
Epistemonikos ID: ead25c0a7c07aa384595284e1572ec811ded4b17
First added on: Jul 18, 2025